Conventional assay methods for discovering and profiling drug-target interactions are typically developed on a target-bytarget basis and hence can be cumbersome to enable and orchestrate. Herein the authors report a solid-state ligand-binding assay that operates in a multiplexed mode to report compound activity against a micorarray-configured panel of G-proteincoupled receptor (GPCR) targets. The pharmacological fidelity of the system is high, and its miniaturized "plug-and-play" format provides improved efficiency both in terms of execution time and reagent consumption. Taken together, these features make the system ideally suited to explore the structure-activity relationship of compounds across a broad region of target class space. (Journal of Biolmolecular Screening 2006:435-438) 
H IGH THROUGHPUT SCREENING (HTS) remains the predominant means of discovering and advancing drug leads. Although the nature of such HTS assays may differ, they share a common practical limitation in that their development and execution are usually managed one target at a time. Paradoxically, this runs contrary to the potential that exists for assay synergy within target classes. This is especially true for integral membrane targets, such as G-protein-coupled receptors (GPCRs), which comprise a major portion of the pharmaceutical industry's target portfolio and for which a large number of assay variations exist. In this regard, binding assays, which directly measure the ability of a test compound to displace a labeled reference ligand, remain a well-accepted screening and characterization tool. In contrast to cell-based functional assays, binding assays are less susceptible to artifacts arising from signal amplification and thus can provide a clearer assessment of a compound's affinity for its target. As conventionally configured, however, both binding and functional assays are costly and cumbersome to use in terms of reagent consumption and labor required to enable and execute them. These practical shortcomings can deny the medicinal chemist the multitarget analyses needed to proactively guide the evolution of lead analogs. To address these issues, we have developed a solid-state microarray-configured method for enabling and executing GPCR binding assays, which provides simultaneous affinity measurements against a collection of targets and more efficiently supports the exploration of structure-activity relationships (SARs).
Previously, we have demonstrated the ability to fabricate microarrays of immobilized GPCR membrane preparations on a γ-aminopropylsilane (GAPS) surface in a manner that preserves pharmacologically well-behaved binding activity. 1, 2 An inherent advantage of such a protein microarray is its potential to efficiently combine both primary screening and selectivity profiling. To achieve this, it is necessary that the ensemble of receptors contained in the array can be assayed simultaneously in a multiplexed format. Herein we address this requirement as we report data demonstrating multiplexed binding assays using a cocktail of fluorescently labeled ligands against a microarray of 10 GPCRs under a standard set of assay conditions that preserves the pharmacological performance of each of the receptors.
MATERIALS AND METHODS

GPCR membranes
Commercial GPCR membrane preparations were obtained from either Euroscreen S.A. (Brussel, Belgium) or Perkin Elmer Life and Analytical Sciences (Boston, MA): apelin (APJR), bradykinin (BK2R), urotensin (UR2R), melanocortin (MC5R), adrenergic (β1R), galanin (Gal2R), motilin (MOTR), neurotensin (NTR1), muscarinic (M1R), and opioid (OP1R).
Fluorescent ligands
The 
GPCR microarrays
Microarrays consisting of 10 different GPCRs printed in triplicate were fabricated according to previously described methods. 1 Briefly, GPCR membrane preparations were adjusted to a final membrane protein concentration of 2 mg/mL, stored in a 384-well microplate reservoir, and robotically deposited using a CMP3 quill pin (Telechem, Atlanta, GA) onto GAPScoated slides in an array configuration using a Cartesian PixSys 5500C arrayer (Cartesian Technologies, Irvine, CA). Approximately 1 nL of each membrane preparation (2 ng membrane protein) was printed in each 100-µm diameter spot (size varying 110-130 µm). The average B max of the membrane preparations used was 3.5 pmol/mg membrane protein (ranging from 0.88-24.6 pmol/mg membrane protein), which equates to an average of 7 × 10 -3 fmol of immobilized receptor binding sites applied at each array address.
GPCR binding assays
Multiplex fluorescent ligand-binding assays were performed by incubating the GPCR microarray with a cocktail containing 10 fluorescent ligands. Approximately 10 µL of ligand cocktail was used to cover each array grid, with each fluorescent ligand in the cocktail present at a concentration at or near its K d (ranging from 0.2-5 nM). An optimized assay buffer was developed for these multiplex binding assays, which produced the maximum binding signal while minimizing "crosstalk" of fluorescent ligands to neighboring noncognate receptors. This buffer contained 50 mM HEPES (pH 7.5), 5 mM MgCl 2 , 1 mM CaCl 2 , 1:40 Perkin Elmer blocking solution A, and 0.05% bovine serum albunim (BSA; w/w). For competitive displacement studies, unlabeled reference compounds were included in the assay cocktail at 5 µM, as indicated in the figure legends. Microarrays were incubated with ligand solutions for 60 min at room temperature before being washed with water, dried, and scanned.
Data capture and analysis
Binding signals were detected using an Axon GenePix 4000B fluorescent scanner. Bodipy-tetramethylrhodamine (BT)and Cy3B-labeled ligands were detected using the standard 532nm laser, whereas Cy5-labeled ligands were detected using the standard 635-nm laser. Quantitation of individual spot intensities was performed using GenePix software. Data were fitted using nonlinear regression software (GraphPad Software, San Diego, CA) to determine IC 50 values and converted to K i values by Cheng-Prusoff correction using the K d values for the respective fluorescent ligands, as determined by Scatchard analysis.
RESULTS AND DISCUSSION
Enabling multiplexed assays using mixtures of labeled ligands requires consideration of several issues: 1) the possible degradation of receptor binding caused by introduction of a label into a receptor's cognate ligand, 2) the extent of crossreceptor reactivity inherent in the labeled ligand, 3) the stringency of assay conditions required to produce pharmacologically relevant binding for each receptor-ligand system, and 4) the ultimate need to arrive at a generic set of assay conditions that support binding signals of suitable strength and fidelity simultaneously for all of the receptors present in the multiplex. To help address these issues, we adopted several guidelines during our selection and design of labeled ligands and receptor systems for the study. For all ligands tested, we chose a K d cutoff of less than 10 nM and a specific binding signal of greater than 80%, as determined by singleplex microspot assays. At assay coefficients of variation (CVs) of approximately 10% to 15%, these criteria usually produce a Z′ of greater than 04, which is marginal for a typical high-throughput screen. 3 For peptide ligands, we chose to label the minimum recognition sequence (when known) that contained at least 1 reactive residue not critical for receptor interaction (e.g., N-terminal amino, lysine epsilon amino, or cysteine thio). A preference for using such truncated peptides was based on our observation that the level of nonspecific binding to the GAPS surface generally increased with peptide length. For nonpeptide ligands, we used wellestablished labeling chemistries as dictated by both the reactive linker moieties and the basic pharmacophore requirements of the molecule. The best linker-dye combination for each ligand was determined empirically. Although the spatial encoding of the microarrays removed an absolute need for spectrally distinct labeled ligands, in cases where a high residual signal for any given receptor membrane preparation was caused by crossreaction with another receptor's labeled ligand, we took advantage of distinct fluorophores to avoid background issues. Figure 1 shows fluorescence images of microarrays composed of the following GPCR systems * : apelin (APJR), 4 bradykinin (BK2R), 5 urotensin (UR2R), 6 melanocortin (MC5R), 7 adrenergic (β1R), 8 galanin (Gal2R), 9 motilin (MOTR), 10 neurotensin (NTR), 11 muscarinic (M1R), 12 and opioid (OP1R). 13 In preliminary experiments, the pharmacology of each of these labeled ligands was individually validated against their cognate receptors in singleplex mode in terms of affinity and selectivity (data not shown). Multiplexed binding assays were then performed using a cocktail of the 10 fluorescent ligands. This ligand cocktail generated positive binding signals for all receptors included on the microarray (Fig. 1A) .
Although the degree of specific binding observed for each receptor was consistent, the absolute signal intensity between different receptor systems did vary. This is most likely attributable to the use of membrane preparations expressing different levels of receptor (B max ranging from 0.88-24.6 pmol/mg membrane protein) and the use of different working concentrations of fluorescent ligands, which themselves had different inherent fluorescent quantum yields. Because our subsequent analysis is based on the proportion of binding that is displaceable by an excess of unlabeled competing ligand, these variances in signal maxima do not compromise data interpretation, providing the window falls within the dynamic range of the scanner. For example, when excess telenzepine (a specific M1R antagonist) was added to this cocktail, only the M1R signal was attenuated ( Fig. 1A) . Similarly, the presence of an excess of urotensin and galanin resulted specifically in decreased fluorescent signal to UR2R and Gal2R, respectively (Fig. 1A) . Histograms quantify the ability to attenuate between 60% and 90% of specific binding for each of the receptors in the array (Fig. 1B) .
We also evaluated the ability of the methodology to quantify ligand affinity when operating in a multiplex mode. Accordingly, dissociation constants for each labeled ligand against its cognate receptor were determined by Scatchard analysis in singleplex mode and then applied to subsequent multiplex displacement experiments. Figure 2A shows fluorescence images of a microarray consisting of the APJR, UR2R, and Gal2R receptors, coincubated with a cocktail of their respective fluorescent ligands. The addition of increasing amounts of unlabeled antagonist for each receptor in the microarray resulted in dosedependent displacement of that receptor's cognate fluorescent ligand. The potencies of the reference compounds tested, as determined by K i values (Cheng-Prusof-corrected; Fig. 2B) , are in reasonable agreement with values determined by radioligand displacement studies (data not shown). Competition curvesfor compounds at unrelated receptors showed no demonstrable dose-dependent displacement behavior, further supporting the ability to simultaneously quantify compound potency and specificity at each of the multiplexed targets in the panel.
In summary, our results demonstrate the ability to enable microarray-configured multiplexed GPCR binding assays that can be used to simultaneously screen and characterize compound collections against a panel of receptor targets. The pharmacological fidelity of the assay is comparable to conventional methods but improves upon conventional methods by enabling parallel target queries in a miniaturized format. These features can effectively accelerate the elucidation of structure-activity relationships for compounds against both the therapeutic target proper and a spectrum of collateral targets of interest. The microarray approach not only increases information content on biological and chemical axes but does so in a way that minimizes turnaround time and reagent consumption. These attributes can most effectively support medicinal chemistry efforts to increase a drug lead's therapeutic efficacy through enhanced target affinity and selectivity. Taken to its logical endpoint, the biological (target) and chemical (compound) throughput afforded by the microarray system has the potential to enable a true chemical-genomics approach to drug discovery. Future exploration of the working limits of the platform will address the minimum target density needed for the immobilized GPCR membranes (both in terms of expression level and spot packing), the practical complexity achievable within a given multiplexed assay, and the long-term stability of the printed slides. Preliminary experiments indicate that the ultimate performance of the platform will significantly exceed the parameters reported in this study.
